Carlos Ramirez

Cooley advised Uber Technologies (NYSE: UBER), a technology platform that uses a massive network, top technology, operational excellence and deep product knowledge to power movement from Point A to Point B, on its offering of $1 billion principal amount of 0% exchangeable senior notes due 2028.

Cooley represented Beta Bionics, a pioneering leader in the development of advanced diabetes management solutions, in its $234.6 million initial public offering and concurrent $17 million private placement.

Cooley advised Tvardi Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the development of novel, oral, small-molecule therapies targeting STAT3 to treat fibrosis-driven diseases, on its definitive merger agreement to combine in an all-stock transaction with Cara Therapeutics (Nasdaq: CARA), a development-stage biopharmaceutical company that has been leading a new treatment paradigm to improve the lives of patients suffering from pruritus.

Cooley advised Uber Technologies, a technology platform that uses a massive network, top technology, operational excellence and product expertise to power movement from Point A to Point B, on its $4 billion investment-grade bond offering.

Cooley advised Candid Therapeutics, a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, on its $370 million debut capital raise and three-way merger with Vignette Bio and TRC 2004.